- Stocks
- Healthcare
- NASDAQ: EPZM

Price (delayed)

$6.96

Market cap

$709.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.47

Enterprise value

$870.84M

The company's revenue rose by 40% QoQ and by 28% YoY

The gross profit has grown by 38% from the previous quarter but it has contracted by 12% YoY

The equity has plunged by 64% YoY and by 33% from the previous quarter

The quick ratio has contracted by 43% YoY and by 9% from the previous quarter

What are the main financial stats of EPZM

Market
Valuations
Earnings

Shares outstanding

101.98M

Market cap

$709.75M

Enterprise value

$870.84M

Price to earnings (P/E)

N/A

Price to book (P/B)

5.76

Price to sales (P/S)

32.15

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

39.51

Revenue

$22.04M

EBIT

-$240M

EBITDA

-$235.25M

Free cash flow

-$249.58M

Per share
Balance sheet
Liquidity

EPS

-$2.47

Free cash flow per share

-$2.45

Book value per share

$1.21

Revenue per share

$0.22

TBVPS

$3.54

Total assets

$406.71M

Total liabilities

$283.68M

Debt

$234.8M

Equity

$123.03M

Working capital

$301.41M

Debt to equity

1.91

Current ratio

8.73

Quick ratio

7.91

Net debt/EBITDA

-0.68

Margins
Efficiency
Dividend

EBITDA margin

-1,067.4%

Gross margin

66.8%

Net margin

-1,139%

Operating margin

-1,081.7%

Return on assets

-59.4%

Return on equity

-118.7%

Return on invested capital

-62%

Return on capital employed

-65.3%

Return on sales

-1,089%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Epizyme stock price performed over time

Intraday

-1.69%

1 week

-4%

1 month

-23.01%

1 year

-50.92%

YTD

-35.91%

QTD

-16.25%

How have Epizyme's revenue and profit performed over time

Revenue

$22.04M

Gross profit

$14.73M

Operating income

-$238.4M

Net income

-$251.03M

Gross margin

66.8%

Net margin

-1,139%

The company's revenue rose by 40% QoQ and by 28% YoY

The gross profit has grown by 38% from the previous quarter but it has contracted by 12% YoY

The gross margin has contracted by 31% YoY

The net income has contracted by 31% YoY and by 8% from the previous quarter

What is Epizyme's growth rate over time

What is Epizyme stock price valuation

P/E

N/A

P/B

5.76

P/S

32.15

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

39.51

The EPS has decreased by 21% YoY and by 8% from the previous quarter

The equity has plunged by 64% YoY and by 33% from the previous quarter

The stock's P/B is 28% above its 5-year quarterly average of 4.5 but 2.4% below its last 4 quarters average of 5.9

EPZM's P/S is 61% below its last 4 quarters average of 82.7 and 58% below its 5-year quarterly average of 75.7

The company's revenue rose by 40% QoQ and by 28% YoY

How efficient is Epizyme business performance

Epizyme's ROE has plunged by 99% YoY and by 36% from the previous quarter

The ROS has increased by 24% from the previous quarter and by 5% YoY

The ROA has contracted by 22% YoY and by 11% from the previous quarter

EPZM's ROIC is up by 13% year-on-year and by 7% since the previous quarter

What is EPZM's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EPZM.

How did Epizyme financials performed over time

The total assets is 43% more than the total liabilities

Epizyme's total liabilities has surged by 155% YoY

The quick ratio has contracted by 43% YoY and by 9% from the previous quarter

EPZM's debt is 91% more than its equity

The equity has plunged by 64% YoY and by 33% from the previous quarter

EPZM's debt to equity is up by 49% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.